TW221296B - - Google Patents

Info

Publication number
TW221296B
TW221296B TW081100879A TW81100879A TW221296B TW 221296 B TW221296 B TW 221296B TW 081100879 A TW081100879 A TW 081100879A TW 81100879 A TW81100879 A TW 81100879A TW 221296 B TW221296 B TW 221296B
Authority
TW
Taiwan
Application number
TW081100879A
Original Assignee
Samdoz Pharmaceutical Factory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samdoz Pharmaceutical Factory filed Critical Samdoz Pharmaceutical Factory
Application granted granted Critical
Publication of TW221296B publication Critical patent/TW221296B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/086—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being alphaMSH, alpha melanocyte stimulating hormone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW081100879A 1991-02-05 1992-02-10 TW221296B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919102450A GB9102450D0 (en) 1991-02-05 1991-02-05 Improvements in or relating to organic compounds

Publications (1)

Publication Number Publication Date
TW221296B true TW221296B (zh) 1994-02-21

Family

ID=10689561

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081100879A TW221296B (zh) 1991-02-05 1992-02-10

Country Status (11)

Country Link
EP (1) EP0498771A3 (zh)
JP (1) JPH04347000A (zh)
AU (1) AU1065392A (zh)
CA (1) CA2060537A1 (zh)
FI (1) FI920456A (zh)
GB (1) GB9102450D0 (zh)
IE (1) IE920357A1 (zh)
IL (1) IL100853A0 (zh)
NZ (1) NZ241496A (zh)
TW (1) TW221296B (zh)
ZA (1) ZA92827B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650134A (en) * 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
DE69423753T2 (de) 1993-05-05 2000-11-02 Keith Rose Polyoximverbindungen und deren herstellung
US6001364A (en) 1993-05-05 1999-12-14 Gryphon Sciences Hetero-polyoxime compounds and their preparation by parallel assembly
KR100999044B1 (ko) 2008-03-26 2010-12-09 한국원자력연구원 킬레이트제 접합 α-ＭＳＨ 펩타이드 유도체, 이의제조방법 및 이를 유효성분으로 함유하는 흑색종 진단 및치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE109793T1 (de) * 1987-05-22 1994-08-15 University Patents Inc Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung.
EP0437487B1 (en) * 1988-10-04 1994-03-09 Cancer Research Campaign Technology Limited Targetting agents
NZ234173A (en) * 1989-06-23 1993-10-26 Cancer Res Campaign Tech Alpha-melanocyte stimulating hormone derivative (alphamsh)-targetted moiety conjugate

Also Published As

Publication number Publication date
EP0498771A3 (en) 1992-11-25
AU1065392A (en) 1992-08-13
IL100853A0 (en) 1992-11-15
EP0498771A2 (en) 1992-08-12
IE920357A1 (en) 1992-08-12
FI920456A (fi) 1992-08-06
JPH04347000A (ja) 1992-12-02
CA2060537A1 (en) 1993-12-15
NZ241496A (en) 1994-09-27
ZA92827B (en) 1993-08-05
GB9102450D0 (en) 1991-03-20
FI920456A0 (fi) 1992-02-03

Similar Documents

Publication Publication Date Title
DK0608366T3 (zh)
FR2681164B1 (zh)
FR2671931B1 (zh)
FR2685100B1 (zh)
FR2676147B1 (zh)
FR2673017B1 (zh)
FR2673252B1 (zh)
CH681761GA3 (zh)
EP0512438A3 (zh)
FR2678330B1 (zh)
DK0520894T3 (zh)
FR2673333B1 (zh)
FR2675070B1 (zh)
FR2681868B1 (zh)
FR2672278B1 (zh)
FR2675750B1 (zh)
FR2680352B1 (zh)
FR2676255B1 (zh)
FR2675678B1 (zh)
FR2674367B1 (zh)
FR2681443B1 (zh)
FR2674650B1 (zh)
FR2681281B1 (zh)
FR2683702B1 (zh)
FR2679328B1 (zh)